New RSV vaccine trial aims to shield seniors from severe lung infections
NCT ID NCT07272434
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 25 times
Summary
This large Phase 3 study is testing an experimental RSV vaccine in 25,000 adults aged 60 and older. The goal is to see if a single shot can prevent lower respiratory tract disease caused by RSV, a common virus that can be dangerous for seniors. Participants will receive either the vaccine or a placebo, and researchers will monitor for safety and immune response over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial Center for Disease Control and Prevention
NOT_YET_RECRUITINGGuangzhou, Guangdong, 511400, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hebei Provincial Center for Disease Control and Prevention
ACTIVE_NOT_RECRUITINGShijiazhuang, Hebei, 050021, China
-
Henan Center for Disease Control and Prevention
RECRUITINGZhengzhou, Henan, 450016, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hubei Provincial Center for Disease Control and Prevention
RECRUITINGWuhan, Hubei, 430079, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hunan Provincial Center for Disease Control and Prevention
RECRUITINGChangsha, Hunan, 410005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shaanxi Provincial Center for Disease Control and Prevention
RECRUITINGXi'an, Shaanxi, 710054, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shandong Province Centers for Disease Control and Prevention
ACTIVE_NOT_RECRUITINGJinan, Shandong, 250014, China
-
Sichuan Center for Disease Control and Prevention
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Recombinant Respiratory Syncytial Virus Vaccine (CHO cell)
What this could lead to
If successful, this could provide a safe and effective vaccine to protect older adults from serious RSV-related lung infections.
What could go wrong
This is a large Phase 3 trial, but the vaccine is still experimental. It may not prove effective or could have side effects not yet seen in earlier studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.